A363250 Stock Overview
Genesystem Co., Ltd., a biotech engineering company, specializes in molecular testing solutions to target on-site testing needs.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Genesystem Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩6,280.00 |
| 52 Week High | ₩32,000.00 |
| 52 Week Low | ₩5,390.00 |
| Beta | 0.62 |
| 1 Month Change | -25.86% |
| 3 Month Change | -25.68% |
| 1 Year Change | -62.97% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -63.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| A363250 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -7.6% | 0.3% | -0.4% |
| 1Y | -63.0% | 5.7% | 4.5% |
Return vs Industry: A363250 underperformed the KR Biotechs industry which returned 5.7% over the past year.
Return vs Market: A363250 underperformed the KR Market which returned 4.5% over the past year.
Price Volatility
| A363250 volatility | |
|---|---|
| A363250 Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A363250's share price has been volatile over the past 3 months.
Volatility Over Time: A363250's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | n/a | www.genesystem.co.kr |
Genesystem Co., Ltd., a biotech engineering company, specializes in molecular testing solutions to target on-site testing needs. The company offers PCR systems, multiplex biochips, and PCR reagents. It also provides human pathogen assays, including novel coronavirus (SARS-CoV-2) detection kits, SARS-CoV-2/Flu/RSV simultaneous detection kits, and mycobacterium tuberculosis detection kits; veterinary diagnostics; food safety assays comprising foodborne pathogen detection kits, HALAL food testing kits, and meat species identification kits; and nucleic acid extraction assays, such as extraction kits, extraction buffers, lysis buffers, and gDNA extraction kits.
Genesystem Co., Ltd. Fundamentals Summary
| A363250 fundamental statistics | |
|---|---|
| Market cap | ₩43.87b |
| Earnings (TTM) | -₩11.27b |
| Revenue (TTM) | ₩1.57b |
28.0x
P/S Ratio-3.9x
P/E RatioIs A363250 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A363250 income statement (TTM) | |
|---|---|
| Revenue | ₩1.57b |
| Cost of Revenue | ₩2.47b |
| Gross Profit | -₩904.72m |
| Other Expenses | ₩10.36b |
| Earnings | -₩11.27b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.61k |
| Gross Margin | -57.76% |
| Net Profit Margin | -719.17% |
| Debt/Equity Ratio | 13.7% |
How did A363250 perform over the long term?
See historical performance and comparison